Fibromuscular Dysplasia Market Research And Analysis By Type, Diagnosis, Treatment and End User -forecast till 2027
Fibromuscular Dysplasia Market Scenario
Fibromuscular dysplasia is also known as FMD, a disease causing the arteries in the body to have an unnatural development of cells. Stenosis .i.e. narrowing of the medium size arteries and Aneurysm i.e. enlargement of the medium sized arteries are the two cause of fibromuscular dysplasia. The U.S. Registry for FMD in 2014 registered that around 200 patients (21.7%) were affected with Aneurysm and analyzed in 237 patients (25.7%) altogether, 384 patients (41.7%) had an aneurysm.
There are various symptoms for fibromuscular dysplasia depend on the affected arteries such as kidney, brain or abdominal. However, if the renal arteries present in the kidney are affected due to symptoms such as high blood pressure, tissues damage in kidneys, chronic kidney failure (rarely).
The extracranial carotid, renal, and intracranial courses were the most widely recognized destinations of an aneurysm; analysis was frequently conducted in the extracranial carotid, vertebral, renal, and coronary conduits. FMD patients analyzed were more youthful at the introduction and experienced more neurological side effects and opposite end-organ ischemic occasions than those without dismemberment. 33% of aneurysm patients (63 of 200) experienced remedial mediation for aneurysm repair.
Fibromuscular dysplasia market report is dominated by many key players like Alkermes Pharma Ireland Limited (Ireland), ALVOGEN (Malta), Aspen Surgical Products, Inc.(the US), Astra Zeneca (UK), B. Braun Melsungen AG(Germany), Bayer Healthcare Pharmaceuticals Inc. (Germany), Becton, Dickinson and Company (US), Bristol-Myers Squibb (US), Dainippon Sumitomo Pharma Co., Ltd (Japan), Ethicon, Inc. (Scotland), Merck (US), Novartis (Switzerland), Pfizer (US), Sanofi-Aventis (France), Smith & Nephew plc.(UK); Medtronic (Ireland), Stryker Corporation (US), and Watson Pharma Private Limited (US).
A study published in 2015 into Imaging constituted that fibromuscular dysplasia widely occurred in the renal arteries which were up to 4% - 6% and in the cervico- encephalic arteries 0.3% - 3%.
In a review combining the results of 4 studies including 3,181, 4.4 % (139 subjects) asymptomatic patients had undergone a renal angiography before kidney transplant donation. In another study among 20,244 consecutive autopsies performed at the Mayo Clinic over a 25-year period, only 4 subjects had cervical FMD (0.02 %). Magnetic resonance angiography (MRA) and CTA present high specifies for detecting renal artery stenosis due to FMD (92 and 84 % respectively), but have relatively low sensitivities (64 and 62 % respectively).
According to Physical Examination Findings in Fibromuscular Dysplasia in America, men in their mid-50 are most likely to cause fibromuscular dysplasia. Out of 447 patients enrolled 18.3% people had arterial dissection and 17.0% had an arterial aneurysm. The symptoms and signs leading to diagnostics of fibromuscular dysplasia were hypertension, headache, pulsatile tinnitus, flank/abdominal pain, cervical bruit, epigastric bruit. The statistics stated that from the 447 examined patients 63.8% had hypertension, 30.2% had Headache, 27.5% had pulsatile tinnitus, 15.7% had flank/ abdominal pain, 22.2% had cervical bruit and 9.4% had epigastric bruit.
According to Jeffrey W. Olin, DO, FACC, FAHA, there is an average delay of 4 to 9 years from the time of the first symptom or sign to a diagnosis of FMD.
The fibromuscular disease affects women more as compared to men but there are chances of men and children getting affected too. Taking age into consideration fibromuscular dysplasia affects the people in their early 50’s. People who smoke have elevated risk of developing fibromuscular dysplasia, and also smoking is a risk factor for patients affected by fibromuscular dysplasia.
Radiologists play an important role in the diagnosis of FMD, and good knowledge of FMD’s signs will certainly help reduce the delay between the first symptoms and diagnosis. The factors that are propelling the market of fibromuscular dysplasia is the rising pervasiveness of the disease and the R&D expenditure in the market. The country-wise R&D expenditure in the pharmaceutical industry was EUR 321 Billion by Germany followed by EUR 237 Billion by France and EUR 223 Billion by the United Kingdom.
The increasing R&D expenditures and the increase in healthcare expenditure by the countries are the key factors that are dominating the fibromuscular dysplasia market along with the daily increasing number of patients.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Contact Us:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com